President Joe Biden is reportedly set to announce a partnership in which Merck (NYSE:MRK) will make Johnson & Johnson’s (NYSE:JNJ) recently approved COVID-19 vaccine.
The Washington Post reported that the agreement between the two competitors will boost the supply of the single-dose vaccine from J&J’s Janssen subsidiary, which received FDA emergency use authorization last week.
Get the full story at our sister site, Pharmaceutical Processing World.
Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease

![A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/06/51187236177_b7b566a401_k-268x170.jpg)

